Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Chong, Jimmy ^a   Haran, Cheyaanthan ^a   Chauhan, Bhupendrasinh F ^b,c   Asher, Innes ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Manitoba SPOR SUPPORT Unit   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO; ANTIASTHMATIC AGENT;

ASTHMA; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HOARSENESS; HUMAN; INCIDENCE; LUNG FUNCTION TEST; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; RISK REDUCTION; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; WHEEZING; ADOLESCENT; ADULT; CHILD; DISEASE COURSE; INFANT; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; HUMANS; INFANT; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85003051189     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011032.pub2     Document Type: Review

References (57)

1. Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. Journal of Allergy and Clinical Immunology 2008; Vol. 122, issue 6:1127-35.e8.
2. Ducharme F, Lemire C, Noya F, Davis GM, Alos N, Leblond H, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. New England Journal of Medicine 2009;360(4):339-353.
3. Ducharme FM, Lemire C, Noya FJ, Davis GM, Alos N, Leblond H, et al. Randomized controlled trial of intermittent high-dose fluticasone versus placebo in young children with viral-induced asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine 2007;175:[A958].
4. Ducharme FM, Lemire C, Noya FJ, Davis GM, Alos N, Leblond H, et al. Safety of intermittent high-dose fluticasone vs. placebo in young children with viral-induced asthma: a multicenter randomized controlled trial [Abstract]. American Journal of Respiratory and Critical Care Medicine 2007;175:[A958].
5. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011; Vol. 377, issue 9766:650-7.
6. Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. New England Journal of Medicine 2007; Vol. 356, issue 20:2040-52.
7. Papi A, Nicolini G, Baraldi E, Boner AL, Cutrera R, Rossi GA, et al. Regular vs prn nebulized treatment for wheeze preschool children [Abstract]. American Journal of Respiratory and Critical Care Medicine 2009; Vol. A4818:[Poster #E34].
8. Papi A, Nicolini G, Baraldi E, Boner AL, Cutrera R, Rossi GA, et al. Regular vs prn nebulized treatment in wheeze preschool children. Allergy 2009; Vol. 64, issue 10:1463-71.
9. Svedmyr J, Nyberg E, Thunqvist P, Asbrink-Nilsson E, Hedlin G. Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Acta Paediatrica 1999; Vol. 88, issue 1:42-7.
10. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. New England Journal of Medicine 2006;354(19):1998-2005.
11. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al. Daily versus as-needed corticosteroids for mild persistent asthma. New England Journal of Medicine 2005;352(15):1519-28. [1533-4406]
12. Durmaz C, Asilsoy S, Usta Guc B. Efficacy of nebulised budesonide in infants with viral wheezing [Abstract]. Allergy 2011;66(s94):563.
13. Haahtela T, Tamminen K, Malmberg LP, Zetterström O, Karjalainen J, Ylä-Outinen H, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. European Respiratory Journal 2006;28(4):748-55.
14. Haahtela T, Tamminen K, Malmberg P, Karjalainen J, Yia-Outinen H, Zetterstrom O, et al. As-needed treatment with a b2-agonist/corticosteroid combination in mild intermittent asthma (SOMA) [Abstract]. European Respiratory Journal 2005;26:Abstract No. 1722.
15. Hamada K, Yasuba H, Tanimura K, Hiramatu M, Kobayashi Y, Kita H. How can we stop ICS? Risk control therapy by as needed inhaled fluticasone after stepping down [Abstract]. Journal of Allergy and Clinical Immunology 2008;121:S219 [844].
16. Jenkins C, Belousova E, Marks G, Reddel H. Intermittent or continuous inhaled corticosteroids for mild asthma?. Respirology (Carlton, Vic.) 2006;11(Suppl 2):Abstract no. 70.
17. Papi A, Nicolini G, Boner AL, Baraldi E, Cutrera R, Fabbri LM, et al. Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children. Italian Journal of Pediatrics 2011;37:39.
18. Turpeinen M, Nikander K, Pelkonen AS, Syvanen P, Sorva R, Raitio H, et al. Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Archives of Disease in Childhood 2008;93(8):654-9.
19. Turpeinen M, Pelkonen AS, Nikander K, Sorva R, Selroos O, Juntunen-Backman K, et al. Bone mineral density in children treated with daily or periodical inhaled budesonide: The Helsinki early intervention childhood asthma study. Pediatric Research 2010;68(2):169-73.
20. Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. New England Journal of Medicine 2011;365(21):1990-2001.
21. Barnes P. Efficacy of inhaled corticosteroids in asthma. Journal of Allergy and Clinical Immunology 1998;102:531-8.
22. Bender B. Overcoming barriers to non adherence in asthma treatment. Journal of Allergy and Clinical Immunology 2002;119:916-23.
23. Bender B, Milgrom H, Apter A. Adherence intervention research: what have we learned and what do we do next?. Journal of Allergy and Clinical Immunology 2003;112:489-94.
24. Brand PL, Baraldi E, Bisgaard H, Boner A, Castro-Rodriguez J, Custovic A, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. European Respiratory Journal 2008;32(4):1096-110.
25. Brussee JE, Smit HA, Koopman LP, Wijga AH, Kerkhof M, Corver K, et al. Interrupter resistance and wheezing phenotypes at 4 years of age. American Journal of Respiratory and Critical Care Medicine 2004; Vol. 169, issue 2:209-13. [1073-449X]
26. British Thoracic Society. British guidelines on the management of asthma, 2012. www.brit-thoracic.org.uk/Guidelines/Asthma-Guidelines.aspx (accessed 5 December 2013).
27. Burgess S, Sly P, Morawska A, Devadason S. Assessing adherence and factors associated with adherence in young children with asthma. Respirology 2008;13:559-63.
28. Bush A, Grigg J, Saglani S. Managing wheeze in preschool children. BMJ 2014;348:g15. [1756-1833]
29. Chauhan B, Chartrand C, Ducharme F. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD009611.pub3]
30. Ducharme FM, Tse SM, Chauhan B. Diagnosis, management, and prognosis of preschool wheeze. The Lancet 2014; Vol. 383, issue 9928:1593-604. [0140-6736]
31. Foresi A, Morelli M, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000;117:440-6.
32. Garner R, Kohen D. Changes in the prevalence of asthma among Canadian children. Health Reports 2008; Vol. 19, issue 2:45-50. [0840-6529]
33. Global Initiative for Asthma (GINA). From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014.pdf (accessed 24 October 2014).
34. Global Asthma Network. The Global Asthma Report 2014. http://www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdf (accessed 24 March 2015).
35. Brozek J, Oxman A, Schünemann H. GRADEpro Version 3.6 for Windows. GRADE Working Group, 2012.
36. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions. Available from www.cochrane-handbook.org.
37. Horak E, Lanigan A, Roberts M, Welsh L, Wilson J, Carlin JB, et al. Longitudinal study of childhood wheezy bronchitis and asthma: outcome at age 42. BMJ 2003; Vol. 326, issue 7386:422-3. [0959-8138]
38. Kelly H, Sternberg A, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, et al. Effect of inhaled glucocorticoids in childhood on adult height. New England Journal of Medicine 2012;367(10):904-12.
39. Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009;64:476-83.
40. Liberati A, Altman DG, TetzlaffJ, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6:e1000100.
41. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. New England Journal of Medicine 1995; Vol. 332, issue 3:133-8. [0028-4793]
42. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD001107]
43. Pauwels R, Lofdahl C, Postma D, Tattersfield A, O'Byrne P, Barnes P, et al. Effect of inhaled formoterol and budesonide on exacerbations in asthma. New England Journal of Medicine 1997;337(20):1405-11.
44. Pauwels R, Pedersen S, Busse W, Tan W, Chen Y, Ohlsson S, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003;361:1071-6.
45. Pearce N, At-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007;62:757-65.
46. Phelan PD, Robertson CF, Olinsky A. The Melbourne asthma study: 1964-1999. Journal of Allergy and Clinical Immunology 2002; Vol. 109, issue 2:189-94. [0091-6749]
47. Pruteanu AI, Chauhan BF, Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009878.pub2]
48. Rand C. Non-adherence in asthma therapy: more than just forgetting. Journal of Pediatrics 2005;146:157-9.
49. Rand C, Bilderback A, Schiller K, Edelman J, Hustad C, Zeiger R. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. Journal of Allergy and Clinical Immunology 2007;119(4):916-23.
50. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
51. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
52. Sharek P, Bergman D, Ducharme F. Beclomethasone for asthma in children: effects on linear growth. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD001282]
53. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. New England Journal of Medicine 2000;343(15):1054-63.
55. Vos T, Flaxman A, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2013;380(9859):2163-96.
56. Zhang L, Axelsson I, Chung, M, Lau J. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. Pediatrics 2011;127(1):129-38.
57. Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: effects on growth. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009471.pub2]